Zinc Protoporphyrin (Zn(II)-protoporphyrin IX) 是一种具有口服活性的，竞争性的血红素加氧酶-1 (HO-1) 抑制剂，显着减弱间苯三酚 (PG) 对 H2O2的保护作用。Zinc Protoporphyrin 可用作个体孕妇和儿童缺铁的筛查标志物，也用于评估人群铁状态与血红蛋白浓度的组合。Zinc Protoporphyrin 具有抗癌活性。
| 生物活性 | Zinc Protoporphyrin (Zn(II)-protoporphyrin IX) is an orally active and competitiveheme oxygenase-1 (HO-1)inhibitor and markedly attenuates the protective effects of Phloroglucinol (PG) against H2O2[1]. Zinc Protoporphyrin is used as a screening marker of iron deficiency in individual pregnant women and children, but also to assess population iron status in combination with haemoglobin concentration[2]. Zinc Protoporphyrin has anti-cancer activity[3]. |
| IC50& Target[1][2] | Human Endogenous Metabolite |
|
体外研究
(In Vitro) | Zinc Protoporphyrin (Zn(II)-protoporphyrin IX; 5 μM; 72 hours) causes the fraction of late apoptotic and necrotic cells increasing from 10.9% in controls to 30.4% after 72 h[3].
Zinc Protoporphyrin (1.25-40 μM; 48 or 72 hours) exerts cystostatic/cytotoxic effects against tumor cells[3].
Zinc Protoporphyrin (2.5, 5 μM; 48 or 72 hours) results in dose- and time-dependent reduction of cells in G1 phase of the cell cycle[3].
Zinc Protoporphyrin (1.25-40 μM; 48 hours) leads to accumulation of cleaved (active) caspase-3[3].
Apoptosis Analysis[3] | Cell Line: | C-26 cells | | Concentration: | 5 μM | | Incubation Time: | 72 hours | | Result: | The fraction of late apoptotic and necrotic cells increased from 10.9% in controls to 30.4% after 72 h. |
Cell Cytotoxicity Assay[3] | Cell Line: | C-26 and MDA-MB231 cells | | Concentration: | 1.25, 2.5, 5, 10, 20, 40 μM | | Incubation Time: | 48 or 72 hours | | Result: | Exerted cystostatic/cytotoxic effects against tumor cells. |
Cell Cycle Analysis[3] | Cell Line: | C-26 cells | | Concentration: | 2.5, 5 μM | | Incubation Time: | 48 or 72 hours | | Result: | Resulted in dose- and time-dependent reduction of cells in G1 phase of the cell cycle. |
Western Blot Analysis[3] | Cell Line: | C-26 cells | | Concentration: | 1.25, 2.5, 5, 10, 20, 40 μM | | Incubation Time: | 48 hours | | Result: | Leaded to accumulation of cleaved (active) caspase-3. |
|
体内研究
(In Vivo) | Zinc Protoporphyrin (12.5, 25, 50 mg/kg for i.p.; 12.5, 50 mg/kg for p.o.; from day 7 to 19) exerts dose-dependent antitumor effects manifested by the retardation of tumor growth[3].
| Animal Model: | BALB/c mice inoculated with C-26 cells[3] | | Dosage: | 12.5, 25, 50 mg/kg for i.p.; 12.5, 50 mg/kg for p.o. | | Administration: | IP or PO; from day 7 to 19 | | Result: | Exerted dose-dependent antitumor effects manifested by the retardation of tumor growth. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | -20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| 溶解性数据 | In Vitro: DMSO : 20.83 mg/mL(33.27 mM;ultrasonic and warming and heat to 80℃) 配制储备液 | 1 mM | 1.5974 mL | 7.9870 mL | 15.9739 mL | | 5 mM | 0.3195 mL | 1.5974 mL | 3.1948 mL | | 10 mM | 0.1597 mL | 0.7987 mL | 1.5974 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 50%PEG300 50% saline Solubility: 1.67 mg/mL (2.67 mM); Suspended solution; Need ultrasonic
*以上所有助溶剂都可在本网站选购。 |
